Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial
Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial
Demonstrated
Synlogic Announces SYNB8802 Will Advance to Phase 1B Proof of Concept Study After Proof of Mechanism Demonstrated in Dietary Hyperoxaluria | News
CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ — Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company